Strides Pharma Q3 FY26: PAT up 131% YoY to Rs 2,081 mn on property sale gain
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts more than Nifty Microcap 250 and 7.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Q3 FY26 consolidated revenue from operations rose 3.5% YoY to Rs 11,946 million; 9M revenue up 4.7% to Rs 35,352 million. Q3 PAT from continuing operations jumped 131% YoY to Rs 2,081 million, boosted by a one-time Rs 1,021 million gain on sale of an investment property. 9M PAT (continuing) grew 37.5% to Rs 4,452 million. Q3 EPS was Rs 21.93 versus Rs 9.56 last year. Results include exceptional items of Rs 33 million, mainly product recall and settlement costs.
Profit growth looks strong but is lifted by a one-off Rs 1,021 mn property gain; core operations also improved QoQ and YoY.